hide
Free keywords:
Aging/drug effects/*pathology
Alzheimer Disease/*enzymology/mortality/*pathology/physiopathology
Amyloid beta-Protein Precursor/*metabolism/toxicity
Animals
Disease Models, Animal
Drosophila Proteins/*antagonists & inhibitors/metabolism
Drosophila melanogaster/drug effects/*enzymology
Genes, Dominant/genetics
Glycogen Synthase Kinase 3/*antagonists & inhibitors/metabolism
Humans
Lithium/pharmacology
Mutant Proteins/toxicity
Nervous System/drug effects/metabolism/pathology
Neurons/drug effects/enzymology/pathology
Peptides/toxicity
Phosphorylation/drug effects
Phosphoserine/metabolism
tau Proteins/metabolism
Abstract:
Abeta peptide accumulation is thought to be the primary event in the pathogenesis of Alzheimer's disease (AD), with downstream neurotoxic effects including the hyperphosphorylation of tau protein. Glycogen synthase kinase-3 (GSK-3) is increasingly implicated as playing a pivotal role in this amyloid cascade. We have developed an adult-onset Drosophila model of AD, using an inducible gene expression system to express Arctic mutant Abeta42 specifically in adult neurons, to avoid developmental effects. Abeta42 accumulated with age in these flies and they displayed increased mortality together with progressive neuronal dysfunction, but in the apparent absence of neuronal loss. This fly model can thus be used to examine the role of events during adulthood and early AD aetiology. Expression of Abeta42 in adult neurons increased GSK-3 activity, and inhibition of GSK-3 (either genetically or pharmacologically by lithium treatment) rescued Abeta42 toxicity. Abeta42 pathogenesis was also reduced by removal of endogenous fly tau; but, within the limits of detection of available methods, tau phosphorylation did not appear to be altered in flies expressing Abeta42. The GSK-3-mediated effects on Abeta42 toxicity appear to be at least in part mediated by tau-independent mechanisms, because the protective effect of lithium alone was greater than that of the removal of tau alone. Finally, Abeta42 levels were reduced upon GSK-3 inhibition, pointing to a direct role of GSK-3 in the regulation of Abeta42 peptide level, in the absence of APP processing. Our study points to the need both to identify the mechanisms by which GSK-3 modulates Abeta42 levels in the fly and to determine if similar mechanisms are present in mammals, and it supports the potential therapeutic use of GSK-3 inhibitors in AD.
